Laila S. Tabatabai, M.D., is the Director of the Houston Methodist Hospital Fracture Liaison Service and Assistant Professor of Clinical Medicine in the Division of Endocrinology, Houston Methodist Hospital in Houston, Texas.  She received her medical degree, with distinction in research, at Albany Medical College in Albany, New York.  Her postdoctoral training included an internship and residency in internal medicine at the University of Maryland Medical Center in Baltimore and a fellowship in endocrinology at Johns Hopkins Hospital in Baltimore.

Dr. Tabatabai is the Program Director of the Houston Methodist Endocrinology Fellowship program.  She is a member of the National Osteoporosis Foundation Ambassadors Leadership Council.  Her didactic teaching includes a focus on the management of metabolic bone disease and osteoporosis and she has presented at national meetings including the American Association of Clinical Endocrinologists (AACE), Endocrine Society, American Society of Bone and Mineral Research and the Endocrine Nurses Society Symposium.  

As the Director of the Fracture Liaison Service, she focuses on providing education to reduce fracture risk and coordinating treatment programs for fracture patients. Dr. Tabatabai has been the recipient of numerous research grants in the area of osteoporosis.  She has authored peer-reviewed publications appearing in the Journal of Clinical Endocrinology and Metabolism and in Endocrine Practice as well as book chapters and abstracts.  She is considered an expert in the field of anabolic agents for treatment of fragility fractures in high-risk osteoporosis patients.

Dr. Tabatabai is the Principle Investigator for the Disease Monitoring Program (UX023-CL401) for burosumab, an anti-FGF23 monoclonal antibody which corrects phosphate homeostasis in individuals with X-linked hypophosphatemic rickets.  She has chaired the Endocrine Society’s CME and MOC-certified educational program on hypophosphatemia.